FK 506 in clinical kidney transplantation.

Abstract

Early reports on the use of FK 506 after kidney transplantation emphasized the ability to stop prednisone in a significant percentage of successfully transplanted patients.1,2 In addition, there was a relative freedom from antihypertensive agents and a tendency toward low serum cholesterol levels. This report will summarize our experience to date with FK 506 in renal transplantation and will compare the results with a nearly concurrent group of patients treated with cyclosporine (CyA)-based immunosuppression.